A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the ...

A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...

Patients with cardiogenic shock were assigned to receive milrinone or dobutamine for inotropic support. There was no significant difference between the two groups in the composite primary outcome of ...

Against expectations, critically ill people in cardiogenic shock fared similarly receiving one widely used inotrope or another in the small DOREMI trial. Patients had the same clinical outcomes on ...